SCHEMBL22897096

SCHEMBL22897096

NC(=O)C(=O)C(Cc1cccs1)NC(=O)c1nsnc1-c1ccncc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CAPN1 P07384 5/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ USP30 Q70CQ3 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.38
▸ POLB P06746 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ LMNA P02545 3/20 0.35
▸ CDC7 O00311 1/20 0.34
▸ DBF4 Q9UBU7 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ HSPA5 P11021 1/20 0.34
▸ HPGDS O60760 1/20 0.34
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22897219 0.94 CAPN1 (0.42) CAPN1RAB9AUSP30ALDH1A1HPGD
SCHEMBL22896857 0.91 ALDH1A1 (0.42) CAPN1RAB9APOLBALDH1A1HPGD
SCHEMBL22896413 0.88 CAPN1 (0.40) CAPN1RAB9AUSP30KDM4EHPGD
SCHEMBL22895969 0.88 CAPN1 (0.38) CAPN1RAB9AUSP30LMNAHSPA5
SCHEMBL22896684 0.86 CAPN1 (0.46) CAPN1CDC7DBF4
SCHEMBL21854216 0.85 CAPN1 (0.52) CAPN1
SCHEMBL22896324 0.85 CAPN1 (0.42) CAPN1RAB9AUSP30POLBSMN1; SMN2
SCHEMBL22896318 0.84 CAPN1 (0.48) CAPN1
SCHEMBL22897217 0.84 IKBKE (0.40) CAPN1RAB9ATBK1POLBALDH1A1
SCHEMBL22897222 0.84 CAPN1 (0.44) CAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885RAB9A 2461/4885USP30 748/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 CAPN1 4/4885RAB9A 2055/4885USP30 531/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885RAB9A 2461/4885USP30 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback